Stockreport

Vaxcyte Announces Pricing of $550 Million Public Offering

Vaxcyte, Inc.  (PCVX) 
PDF SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an unde [Read more]